| Document |
Document Title |
|
WO/2023/148501A1 |
The present invention relates to compounds of formula (I) that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2023/149666A1 |
The present invention relates to a composition for improving muscle strength, comprising, as an active ingredient, an Aureobasidium pullulans fermentation product produced by culturing Aureobasidium pullulans SM2001 (accession number KCC...
|
|
WO/2023/149038A1 |
A compound or a pharmaceutically acceptable salt thereof of the present invention has a structure represented by formula (I) and can form a ligand in a drug delivery system formulation. The drug delivery system formulation according to t...
|
|
WO/2023/148203A1 |
The invention relates to a pharmaceutical composition comprising a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting aft...
|
|
WO/2023/141710A1 |
The present disclosure relates generally to DG9 peptide-conjugated splice modulating therapies for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.
|
|
WO/2023/145735A1 |
Provided is a new therapy/prevention for aging-related disorders including sarcopenia. The present invention pertains to a pharmaceutical composition that contains an expectorant (examples thereof include compounds, or pharmaceutically a...
|
|
WO/2023/141721A1 |
The present invention relates to an anticholinergic compound such as Darifenicin for use in the treatment of a neuromuscular disorder (in particular amyotrophic lateral sclerosis or ALS) in a human subject, wherein the neuromuscular diso...
|
|
WO/2023/141408A1 |
A method for promoting muscle regeneration in a subject comprises administering beta-hydroxy beta-methylbutyrate (HMB) and at least one citrus flavonoid to the subject.
|
|
WO/2023/140407A1 |
The present invention relates to a pharmaceutical composition for preventing or treating sarcopenia. More specifically, by comprising coumestrol or pharmaceutically acceptable salt thereof, muscle strength and endurance can be increased ...
|
|
WO/2023/141586A1 |
Disclosed herein are lipid nanoparticle (LNP) compositions encapsulating nucleic acid constructs for systemically delivering muscle proteins or protein complexes to muscle tissues.
|
|
WO/2023/139557A1 |
Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expre...
|
|
WO/2023/140406A1 |
The present invention relates to a pharmaceutical composition for preventing or treating sarcopenia. More specifically, by comprising β-sitosterol or pharmaceutically acceptable salt thereof, muscle strength and endurance can be increas...
|
|
WO/2023/138502A1 |
Provided is an oligonucleotide modulator for preventing or treating dystrophin-deficient-related disorders (DDD) including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The oligonucleotide modulator comprises a s...
|
|
WO/2023/137985A1 |
Disclosed in the present invention are a dietary nutrition supplement for regulating skeletal muscle glucose metabolism and mitochondria generation and a use thereof. Active ingredients of the dietary nutrition supplement comprise a thea...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
|
WO/2023/134146A1 |
The present invention relates to regulation and promotion of body tissue growth, regeneration and healing by a lactic acid or a polylactic acid, and provides a novel tissue injury prevention and treatment mode, which can be used for tiss...
|
|
WO/2023/136668A1 |
The present invention relates to a composition for improving athletic performance or preventing, alleviating or treating muscular diseases, containing an extract of Gynostemma pentaphyllum leaves as an active ingredient. The composition ...
|
|
WO/2023/137420A1 |
This disclosure provides crystalline forms of an androgen receptor modulator of formula and methods of making and using these forms.
|
|
WO/2023/133726A1 |
Provided herein is a method for reprogramming or inducing presomitic mesoderm progenitor cells from urine cells, a somitoid structure formed by the presomitic mesoderm progenitor cells and uses thereof.
|
|
WO/2023/136669A1 |
The present invention relates to a composition for improving exercise performance, or preventing, ameliorating or treating muscle disease, the composition comprising a gypenoside compound as an active ingredient. The composition of the p...
|
|
WO/2023/131579A1 |
The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of congenital muscular dystrophies, especially Duchenne muscular dystrophy or Becker mu...
|
|
WO/2023/132516A1 |
The present invention relates to a pharmaceutical composition for preventing or treating muscle disease, comprising sulpiride as an active ingredient. The pharmaceutical composition can effectively inhibit muscular atrophy and thus can b...
|
|
WO/2023/130875A1 |
A botulinum toxin protein composition, comprising a botulinum toxin protein and a protein stabilizer. The protein stabilizer is selected from any one of amino acids and amino acid-like compounds, the amino acids being one or more of L-hi...
|
|
WO/2023/127814A1 |
The present inventors have studied and found that the substituted quinoline derivatives have acetylcholine receptor clustering-inducing action and can be useful as an active ingredient in the pharmaceutical compositions for preventing an...
|
|
WO/2023/129377A1 |
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of having, a heart attack (also called a myocardial infarction). For example, one or more inhibitors of a period circadian protein (P...
|
|
WO/2023/124091A1 |
The present invention relates to a use of flunarizine and a method for controlling the number of intercellular mitochondria. The use comprises a use of the flunarizine in the removal of the intracellular mitochondria, and a use of the fl...
|
|
WO/2023/128197A1 |
The objective of the present invention is to provide a composition for preventing or treating muscle diseases, comprising a Jeju Udo peanut sprout extract as an active ingredient, wherein the Jeju Udo peanut sprout extract is used to tre...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/118164A1 |
Haloperidol, or a pharmaceutically acceptable salt, ester or solvate thereof, as well as pharmaceutical compositions comprising the same, for use in methods for preventing and/or treating spinal muscular atrophy, are described.
|
|
WO/2023/121446A1 |
The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line w...
|
|
WO/2023/121444A1 |
The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line w...
|
|
WO/2023/121384A1 |
The present invention relates to a composition comprising a miR-499-5p activator for preventing or treating Duchenne muscular dystrophy, wherein the miR-499-5p activator promotes miR-499-5p expression by expressing MMP-1 in myotubes and ...
|
|
WO/2023/117659A1 |
The present disclosure generally relates to methods and compositions comprising urolithin that treat or prevent a disease or condition associated with muscle decline and/or a kidney dysfunction. Moreover, methods and compositions compris...
|
|
WO/2023/115149A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis, and/or inhibi...
|
|
WO/2023/117990A1 |
The present invention relates to succinate salts of N-(3-(4-(3- (diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[t/]i
midazol-2-amine and pharmaceutically acceptable solvates thereof, for use in the treatment and/or prevention of ...
|
|
WO/2023/115150A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis and/or inhibit...
|
|
WO/2023/121445A1 |
The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line w...
|
|
WO/2023/122803A1 |
Provided herein is a recombinant AAV (rAAV) comprising an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5' inverted terminal repeat (ITR), an expression cassette comprising an open reading fr...
|
|
WO/2023/112025A1 |
The present invention provides methods for to sex-specific treatment and dose titration of diseases associated with an aberrant functionality of activity -dependent neuroprotective protein (ADNP) and/or cytoskeleton such as progressive s...
|
|
WO/2023/113023A1 |
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a phar...
|
|
WO/2023/113402A1 |
The present invention relates to a composition for alleviating, preventing or treating muscle diseases. The composition of the present invention includes dioscin as an active ingredient, and thus is more effective in alleviating, prevent...
|
|
WO/2023/110874A1 |
The invention is directed to Cefuroxime, an antibiotic belonging to the family of cephalosporins, as a novel D2 specific inhibitor able to counteract D2 activation in a number of diseases.
|
|
WO/2023/109471A1 |
Provided are a compound as represented in general formula (I), and a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate or a pharmaceutically acceptable salt or a precursor drug thereof, and a preparatio...
|
|
WO/2023/108025A1 |
Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the pre...
|
|
WO/2023/108137A1 |
An isolated protein comprising a mutant soluble activin II receptor (ActRIIA or ActRIIB) extracellular domain (ActRIIA-ECD or ActRIIB-ECD), wherein said mutant soluble ActRIIA-ECD or ActRIIB-ECD comprises a mutation to remove the N-linke...
|
|
WO/2023/106645A1 |
The present invention relates to a composition for preventing, alleviating, or treating muscular diseases containing ginsenoside Rg5. The composition promotes the differentiation of myoblasts to increase muscle mass, has a muscle regener...
|
|
WO/2023/106009A1 |
The present invention is to provide a beta-glucan, a composition comprising the beta-glucan, and a method of use of the beta-glucan, for improving, preventing and/or treating muscular dystrophy.
|
|
WO/2023/105387A1 |
Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such com...
|
|
WO/2023/107611A1 |
The disclosure provides methods for treating muscular dystrophy (MD), such as Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) in a mammalian subject. The methods comprise administering to the subject an effective amo...
|
|
WO/2023/102519A1 |
Provided herein are methods and compositions for treating succinic semialdehyde dehydrogenase deficiency (SSADHD) using gene therapy to restore, at least partially, expression and/or activity of succinic semialdehyde dehydrogenase (SSADH).
|
